Little is known about pediatric Clostridium difficile infection (CDI) epidemiology. We describe the clinical and microbiological characteristics of CDI among hospitalized children in the Netherlands.
METHODS

Study Design
We included all CDIs reported between May 2009 and May 2015 by 26 Dutch hospitals that participate in a national sentinel surveillance study (no ethical approval needed). Hospitals were requested to register all hospitalized patients who fulfilled the clinical CDI definition listed below. Children aged <2 years were excluded. For each CDI patient, information on the history of CDI <8 weeks prior to the current infection, the location of onset (community or hospital), and CDI severity was collected. Antibiotic use prior to CDI onset (for treatment of infections other than CDI) at time of or during admission was registered. Polymerase chain reaction (PCR) ribotyping was used to characterize C. difficile isolates. Thirty days after diagnosis, complications, including surgery and admission to an intensive care unit due to CDI and mortality, were assessed. Additionally, hospitals reported the primary CDI diagnostic test applied during participation (possibly limiting surveillance sensitivity).
Definitions
A pediatric CDI was defined as the occurrence of diarrhea (3 or more loose stools per day for 2 subsequent days) or a toxic megacolon and a positive test for a toxin-producing C. difficile or presence of pseudomembranous colitis in children aged 2-18 years. Other causes of diarrhea were excluded (by chart review and/or results of diagnostic tests for other enteropathogens). Patients aged ≥18 years who fulfilled the same criteria were categorized as "adults" with CDI. A case was considered as healthcare-onset CDI (HO-CDI) if symptoms started in a hospital or long-term care facility and as community-onset CDI (CO-CDI) if symptoms started at home. Severe CDI (for both children and adults) was defined as either the presence of bloody diarrhea and/or pseudomembranous colitis, and/or diarrhea accompanied by dehydration (as judged by the treating physician) and/or hypoalbuminemia (<20 mg), and/or fever (≥38.0°C) with leukocytosis (>15.0 × 10 9 /L). Mortality was considered as "contributable to CDI" if other comorbidities would not have caused death or "partly contributable to CDI" if both CDI and other comorbidities caused death.
Laboratory Methods
The primary (first) diagnostic test of each participating hospital was variable for many hospitals (Supplementary Table 1) . Positive samples were sent to the central laboratory (Leiden University Medical Centre, the Netherlands) for typing. Realtime PCR was used to identify the GDH (glutamate dehydrogenase) gene specific to C. difficile [22] , and PCR ribotyping was used to characterize the isolates [23] .
To study relatedness of the predominant pediatric PCR ribotype 265 in more detail, multiple-locus variable-number tandem-repeat analysis (MLVA) was applied [24] . We selected all ribotype 265 strains from children with CDI included in this study and from 2 preceding and 2 successive adult ribotype 265 cases in the same hospital (also from cases typed apart from the sentinel surveillance study). MLVA results were visualized in a minimum spanning tree using BioNumerics software, version 7.1 (Applied Maths, Saint-Martens-Latem, Belgium). All ribotype 265 isolates were tested for deletions in the TcdA gene using PCR [25] . The genetic relatedness of PCR ribotype 265/ sequence type 88 to other C. difficile types was visualized in a phylogenetic tree, using multilocus sequence typing (MLST) results of the Clostridium difficile MLST Databases. Further, we requested international collaborators (eg, the ESCMID Study Group for Clostridium difficile, founders of the Clostridium difficile MLST Databases, Webribo, and the US Centers for Disease Prevention and Control) to verify the presence of ribotype 265 in their databases by sharing the capillary electrophoresis PCR ribotyping peak file.
Statistical Analyses
Categorical or binary variables were reported as frequencies and percentages and compared based on their 95% confidence intervals (CIs). Continuous variables were reported as medians and the interquartile ranges (IQRs). Quantile regression was used to assess associations between age and covariables. To evaluate a time trend of pediatric CDI, the monthly number of reports was analyzed using a mixed-effect Poisson model, allowing random effects per hospital, to account for clustered data. Additionally, we corrected for the type of primary diagnostic test applied (categorized in free toxin detection, tests including GDH detection, or Nucleic acid amplification test (NAAT)). Complete case analysis was performed, except for 1 sensitivity analysis on CO-CDI vs HO-CDI and prior antibiotic usage. Data were analyzed using Stata software, version 12.1 (StataCorp LP, College Station, Texas).
RESULTS
Pediatric CDI Reporting and Time Trends
Between May 2009 and May 2015, 4691 CDIs were reported. A total of 135 pediatric CDIs (3% of all CDIs) were reported by 17 hospitals (65%). There were large interhospital differences in the proportion of pediatric CDIs, especially when university hospitals (range, 1.8%-14.3%) were compared with nonuniversity hospitals (range, 0%-7.7%; Supplementary Table 1) . No CDI outbreaks on pediatric wards were reported. The number of pediatric CDIs per month was stable according to mixed-effect Poisson modeling (P = .578), also when correcting for the type of primary diagnostic test applied (P = .145).
Clinical Characteristics and 30-Day Outcome
The median age of children with CDI was 10 years (IQR, 4.7-14.5 years) and similar for children with CO-CDI and HO-CDI (11 vs 10 years [P = .84]). Fifty-three percent of the children with CO-CDI received non-CDI antibiotics prior to CDI onset (28/53 [95% CI, 39.1%-66.6%]) compared with 81% of the children with HO-CDI (43/53 [95% CI, 70.4-91.9%]), though information on antibiotic use was missing for 29 cases. If we assumed that all children with missing information either used or did not use non-CDI antibiotics prior to CDI onset, the difference persisted (66% vs 84% and 38% vs 70%, respectively).
A total of 39 children (31%, data for 8 children missing) met the criteria for having severe CDI. Eighteen of these children were dehydrated or had hypoalbuminemia (46%), 16 had bloody diarrhea (41%), 10 had fever and leukocytosis (26%), and 5 had pseudomembranous colitis (13%). Females had severe CDI more often than males (45% [95% CI, 31.8%-58.2%] vs 19% [95% CI, 9.5%-28.2%]).
A complicated course within 30 days after diagnosis was reported for at least 3 children (3%, data of 37 children missing). One 6-year-old female was admitted to the intensive care unit suffering from CDI with dehydration/hypoalbuminemia and fever with leukocytosis. Two males died within 30 days after diagnosis due to causes other than CDI.
Pediatric CDI Compared With Adult CDI
In Table 1 , clinical data of children are compared with those of adult CDI patients (n = 4556). CO-CDI was more common in children than in adults (55% 
PCR Ribotyping Distribution
For 113 of 135 pediatric CDIs (84%), a stool sample or C. difficile isolate was sent to the reference laboratory for PCR ribotyping. Clostridium difficile was detected in 98 samples (n = 5 culture negative; n = 10 Clostridium species but not C. difficile). In total, 36 different C. difficile PCR ribotypes were identified. 14 .5%], respectively). Ribotype 027 strain was not found in the pediatric population but was present in 3% of the adult population (n = 94 [95% CI, 2.1%-3.2%]). The differences in ribotype distribution were larger when HO-CDI was compared with CO-CDI ( Table 2) .
PCR Ribotype 265
Pediatric ribotype 265 cases occurred in 7 hospitals located in different regions of the Netherlands (Figure 1 ). Two-thirds of the cases occurred between March 2012 and March 2013 (n = 10), dispersed over several months. Ribotype 265-infected children were younger than those infected by other ribotypes (median age of 4 vs 11 years). Children and adults with a ribotype 265 CDI (n = 15 and n = 45) did not have more severe CDI compared with those infected by other ribotypes (29% vs 31% and 28% vs 24%, respectively) and did not have a higher 30-day mortality risk (0% vs 4% and 14% vs 14%, respectively). None of the ribotype 265-infected adults deaths were partly related to CDI.
MLVA showed that three-fourths of the ribotype 265 strains isolated from children and adults were genetically related (defined as ≤10 summed tandem-repeat difference [24] ; Figure 1 ). Three clonal complexes (defined as ≤2 summed tandem-repeat difference on ≤2 loci [24] ) were found, of which 2 complexes included adult and pediatric isolates from different hospitals. Three children had a recurrent ribotype 265 infection (Figure 1 ). Three ribotype 265 strains that were isolated in 1 e Data missing for 8 children.
f Data missing for 37 children. Minimum spanning tree of Clostridium difficile polymerase chain reaction ribotype 265 strains isolated from children (in blue; n = 15) and adults (in green; n = 24), according to multiple-locus variable-number tandem-repeat analysis. The STRD is shown between the circles. Dark gray areas represent a cluster of genetically related strains (defined as ≤10 summed tandem-repeat difference), and light gray areas represent clonal complexes (defined as ≤2 summed tandem-repeat difference on ≤2 loci). Each circle specifies the code for the hospital where the patient was located and the month and year of isolation. Superscripts indicate samples that were isolated from identical patients (a, b, and c). Abbreviations: STRD, summed tandem-repeat difference; U, H (U indicates University hospitals and H primary and secondary care hospitals, see Supplementary Table 1) . The 8 most common ribotypes (n ≥3 isolates) in children were taken as a reference, and ribotype 027 was included for its clinical relevance. A dash indicates a zero.
Abbreviations: CO, community onset; HO, healthcare onset. a Two adults had a mixed infection, the polymerase chain reaction ribotype with the lowest number is reported in the table.
university hospital (U3) in October 2012-November 2012 were genetically, but not clonally, related. Ribotype 265 had an intact toxin B production but lacked toxin A due to a TcdA 1.8 kb deletion as ribotype 017 [25] and was negative for binary toxin genes. A phylogenetic tree of multilocus sequence types submitted to the Clostridium difficile MLST Databases illustrated the genetic relatedness of ribotype 265 (assigned as sequence type 88) and ribotype 017 (assigned as sequence type 37; Supplementary Figure 2) . According to the survey in our international network, ribotype 265 appears to be very uncommon or absent in other countries, except for Belgium (Supplementary Table 2 ). In Belgium, ribotype 265 was primarily found isolated from children aged <2 years.
DISCUSSION
We report the clinical characteristics and PCR ribotypes of pediatric CDI in a large sentinel surveillance study in the Netherlands during a 6-year period.
In contrast with several studies performed in the United States [10, 14, 17, 19] and Italy [26] but in agreement with a recent study in the United Kingdom [24] , we did not find an increase in pediatric CDIs over time. The increase in the United States could be related to the high prevalence of NAP1/ribotype 027 or to an increased awareness of the need to test children for CDI, though this is opposed by 1 study [17] . The recent implementation of NAAT in many laboratories may have contributed to this increase [27] by possibly including C. difficile carriers as CDIs. It did have a significant effect on pediatric CDI reporting in our analysis and was incorporated into our model. However, both the unadjusted and adjusted models did not indicate an increase in pediatric CDIs.
We found large interhospital differences in the proportion of reported pediatric CDIs, especially between university hospitals and nonuniversity hospitals (5% vs 0.3%). University hospitals indeed treat children with a higher CDI risk, such as those with cancer, as well as organ and bone marrow transplantation patients [21] . However, we questioned whether nonuniversity hospitals actually did test for C. difficile in children. We contacted 9 hospitals that do not or rarely report pediatric CDI; 1 did not test for CDI in children, but 7 tested on clinical request in children of all ages, and 1 only in patients aged >2 years. There is no guideline for CDI testing in children in the Netherlands (or in Europe) in contrast to the United States [4, 28] . We assume that differing views among both pediatricians and microbiologists on CDI testing in children contributed to interhospital differences.
The clinical characteristics of pediatric CDI found in our study resemble findings of other studies, despite the higher median age of patients in our study [9, 13, 17, 18, 20] . Approximately half of the pediatric cases had CO-CDI, which is in line with 2 studies that used different criteria (29% and 54%) [9, 18] , while others found 26% and 71% of pediatric CDI cases to be acquired in the community [13, 15] . Antibiotics are considered to be a risk factor but not a prerequisite for developing pediatric CDI [21] . In our study, 67% of the children received non-CDI antibiotics prior to CDI onset, which is similar to previous studies that showed rates of 61%-74%, depending on the measured time period of exposure [14, 18] . As expected, the percentage exposed to non-CDI antibiotics was lower in pediatric CO-CDI than in HO-CDI.
Compared with adults, we found a high proportion of severe CDI (31%) in children but a lower complication and mortality rate 30 days after diagnosis. Possibly, children are more capable than adults of recovering from severe CDI [21] or possibly the current severity criteria do not fit the pediatric population [29] . This is supported by a study that revealed that 50% of children with CDI did not require specific CDI treatment, while 76% were classified as "severe CDI" [24] . However, the severity rate in that study was much higher than in our study, and as described in literature [13] [14] [15] .
PCR ribotype 265 (toxin A negative due to a TcdA 1.8 kb deletion, toxin B positive, and negative for binary toxin genes) was most prevalent in children and rarely found in adults. Epidemiological and molecular typing data could not elucidate ribotype 265 transmission routes. MLVA showed that threefourths of the ribotype 265 strains isolated from children and adults were genetically related. There was no clustering according to host (children vs adults), date, or place of isolation. These results suggest ongoing (regional) transmission between the 2 populations, whereas this ribotype may favor younger hosts in particular. In Europe, ribotype 265 was initially observed in Leiden in 2006 and determined to be a new ribotype at the Anaerobe Reference Laboratory in Cardiff (personal communication, Dr Michael Perry) in 2010. In the United States, it was first isolated in 1988 (personal communication, Dr Jane Marsh) using MLST and belongs to the same lineage as ribotypes 017, 047, 088, 130, and 172 (Supplementary Figure 2) [30] . Our international survey showed that this ribotype was rarely found in North America and Europe, except for the neighboring Belgium where most were isolated from children aged <2 years. Although we did not include children aged <2 years in our study (as many other studies), these findings support our hypothesis that the ribotype favors younger hosts and that transmission may be restricted to certain countries.
After ribotype 265, ribotype 014/020 was most often detected in children (12%), consistent with previous studies where NAP4/ PCR ribotype 014 was predominant in 26% and 24% [13, 31] . Another study showed PCR ribotype 014 to be predominant in infants (aged <2 years) in 25% in Spain [32] . Our study, as well as a German study [31] , indicated an absence of ribotype 027 in children in contrast to adults, though both studies typed a limited number of children. In contrast, NAP1/ribotype 027 was found in 11% and 23% of the pediatric CDI cases in the United States and Canada [13, 15] , including community-acquired CDI [15] . In a different single-center US cohort, NAP1/ribotype 027 was found in <1% of the children, opposed to 31% of adults in the same area [33] . These geographical differences may be due to diverse antibiotic exposure (eg, fluoroquinolones), infection prevention measures, or infection pressure in the community.
Our study has several limitations. CDI testing of children was not as well standardized as for adults and may have resulted in a general underestimation of the burden of pediatric CDI. Our definition of community-onset CDI, which was introduced in 2009 for feasibility reasons, differs from international guidelines and hampers benchmarking. Our sample size was relatively small, hampering multivariate analysis, and we had high levels of missing data for some variables. Age-specific denominator data to calculate age-stratified incidence rates were not available, though we evaluated the monthly number of pediatric CDIs using a mixed-effect Poisson model, corrected for the primary diagnostic method applied, and showed that no variation in time was present. In addition, the number of pediatric admissions in the Netherlands [34] did not change over time. The absence of epidemiological links between ribotype 265 cases may be caused by incomplete sampling (eg, nondiagnosed children and asymptomatic carriers) and the lack of detailed patient data, although a dispersion in time and location was evident.
In conclusion, we did not observe an increase in the monthly number of reported pediatric CDIs over a 6-year period. Clostridium difficile ribotype 265 was more prevalent in children than in adults, without a clear explanation. Future prospective pediatric studies are needed to obtain more detailed information on CDI risk factors, transmission, and treatment in children and to confirm and elucidate why some PCR ribotypes are more or less abundant compared with adults.
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